Breast cancer is one of the major causes of death for women in the United States. Overexpression of the c-erb B2 oncogene was reported to correlate positively with poor survival for breast and ovarian cancer patients. It is also known that c-erb B2 overexpression can enhance metastatic potential of human cancer cells and induce resistance to chemotherapeutic agents. Therefore, c-erb B2 oncogene is an excellent target for novel anti-cancer agents for c-erb B2 overexpressing cancer cells. The applicant and coworkers have previously shown that the adenoviral E1A gene functions as a tumor suppressor for the c-erb B2-overexpressing cancer cells through repression of c-erb B2 transcription. During the previous period of support, the applicant demonstrated that with the appropriate delivery system such as cationic liposome or adenovirus vectors, E1A can suppress tumor formation and prolong survival time in tumor-bearing mice. Based on these results, an investigation new drug (IND) was filed at the FDA and phase I gene therapy trials were approved by the FDA and NIH Recombinant DNA Advisory Committee (RAC). Phase I trial entitled, """"""""Phase I Study of E1A Gene Therapy for Patients with Metastatic Breast or Ovarian Cancer That Overexpress c-erb B2"""""""" has recently been initiated at the applicant's institution. This competing renewal application will further investigate the E1A tumor suppression function by modification of the E1A gene to enhance tumor suppression function and reduce potential side effects (if any), development of a specific expression vector to express E1A only in the target breast cancer cells and examination of the hypothesis that E1A, through repression of c-erb B2 can sensitize response of breast cancer cells to chemotherapeutic drugs. The outcomes from this application will lay scientific foundation and are critical for the design of phase II and phase III clinical trials in the future. The long-term goal of this application is to develop novel therapeutic approaches for patients with breast cancer.
The specific aims of this application are: (1) improvement of tumor suppression activity of E1A in c-erb B2-overexpressing breast cancer cells, (2) localization of the functional region of the E1A gene that can inhibit c-erb B2 overexpression and c-erb B2-induced malignancy, (3) to test potential synergistic effects of E1A gene therapy in chemotherapy for breast cancer cells with enhanced c-erb B2 expression and (4) the development of vectors for preferential expression of E1A and c-erb B2-overexpressing breast cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA058880-06
Application #
2895005
Study Section
Special Emphasis Panel (ZRG2-ET-2 (03))
Program Officer
Wolpert, Mary K
Project Start
1993-02-02
Project End
2001-01-31
Budget Start
1999-08-01
Budget End
2001-01-31
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Biology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Lee, Dung-Fang; Kuo, Hsu-Ping; Chen, Chun-Te et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130:440-55
Yang, Jer-Yen; Xia, Weiya; Hu, Mickey C-T (2006) Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 29:643-8
Kumar, Rakesh; Hung, Mien-Chie (2005) Signaling intricacies take center stage in cancer cells. Cancer Res 65:2511-5
Hu, Mickey C-T; Hung, M C (2005) Role of IkappaB kinase in tumorigenesis. Future Oncol 1:67-78
Li, Yan M; Zhou, Binhua P; Deng, Jiong et al. (2005) A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 65:3257-63
Ding, Qingqing; Xia, Weiya; Liu, Jaw-Ching et al. (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19:159-70
Shao, Ruping; Lee, Dung-Fang; Wen, Yong et al. (2005) E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol Cancer Res 3:219-26
Liao, Yong; Hung, Mien-Chie (2004) A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. Cancer Res 64:5938-42
Hu, Mickey C-T; Lee, Dung-Fang; Xia, Weiya et al. (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117:225-37
Zhou, Binhua P; Deng, Jiong; Xia, Weiya et al. (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6:931-40

Showing the most recent 10 out of 89 publications